Roche says FDA grants priority review to hemophilia drug emicizumab
ZURICH (Reuters) - Swiss pharma group Roche said the U.S. Food and Drug Administration (FDA) granted priority review to its emicizumab for hemophilia A with inhibitors.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Food and Drug Administration (FDA) | Grants | Haemophilia | Health | Hemophilia | Pharmaceuticals | Switzerland Health